International Journal of Molecular Sciences·Nov 17Machine Learning-Guided Design of Peptide-Targeted CRISPR Vectors for Tissue-Specific Non-Coding RNA KnockdownReviewInterventionsPaper
Annual Review of Medicine·Nov 16RNA Therapeutics in Cardiovascular Medicine: From Molecular Mechanisms to Clinical PracticeReviewCardiovascular diseasePaper
Frontiers in Endocrinology·Nov 5Comparative efficacy and safety of PCSK9-directed therapies, RNA-based lipid therapies, and muvalaplin for lipoprotein(a) lowering: a systematic review and network meta-analysisMeta-analysis of randomized trialsMuvalaplinPaper
International Journal of Cardiology Cardiovascular Risk and Prevention·Nov 1Lipoprotein(a): Bridging the gap between risk prediction, measurement, and emerging therapeuticsReviewInterventionsPaper
Frontiers in Medicine·Oct 30RNA therapeutics for muscle wasting: bridging target validation and muscle-directed deliveryAccepted, not yet published: reviewMuscle wastingPaper
Current Cardiology Reports·Oct 29Are Injectable Antihypertensives the Answer to Improving Blood Pressure Control: SiRNAs and Antisense Oligonucleotide AgentsReviewAntisense oligonucleotidesPaper
Biomedicines·Oct 27Lipoprotein(a) and Plaque Vulnerability: Mechanistic Insights, Imaging Evidence, and Clinical ImplicationsReviewMechanismsPaper
Biomedicines·Oct 27Lipoprotein(a) After Myocardial Infarction: Residual Risk, Measurement, and the Unresolved Therapeutic QuestionReviewMyocardial infarctionPaper
ESC Congress 2026 Abstract·Oct 26RNA targeted therapies for lipoprotein(a) lowering: systematic review and meta analysis of siRNA and antisense oligonucleotidesMeta-analysis of randomized trialsAntisense oligonucleotidesPaper
Reviews in Cardiovascular Medicine·Oct 11Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future DirectionsReviewInterventionsPaper
Frontiers in Pharmacology·Oct 2Lipoprotein(a) in the statin era: from risk marker to therapeutic targetReviewInterventionsPaper
Journal of Clinical Medicine·Sep 15Lipoprotein(a) in Personalized Cardiovascular Prevention: Risk Stratification, Coronary Artery Calcium, and Emerging Lp(a)-Lowering TherapiesReviewCoronary artery calciumPaper
American Journal of Cardiovascular Drugs·Sep 1Lipoprotein(a): Cardiovascular Risk and Emerging Targeted TherapiesReviewAtherosclerotic cardiovascular diseasePaper
Biomedicines·Aug 27Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic PerspectivesReviewInterventionsPaper
bioRxiv·Aug 20Cytoplasmic DNA Sensing Links LINE-1 Expression to Neuronal Senescence in Alzheimer's DiseasePreprint: experiments in human cellsCellular senescencePaper
Diagnostics·Aug 13Decoding Primary Hyperlipoproteinemias: A Focus on the Pathogenesis and Diagnosis of Familial Hypercholesterolemia and Familial Combined HyperlipidemiaReviewMechanismsPaper
Internal and Emergency Medicine·Aug 10Lipopotrein(a): from the complex metabolism to the optimal lowering drugReviewInterventionsPaper
Ageing Research Reviews·Jun 18Biomarkers and therapies associated with Hutchinson-Gilford Progeria SyndromeReviewProgeriaPaper
Eye Discovery·May 16Precision engineering for ocular gene therapy: Molecular tools, delivery platforms, and disease applicationsReviewInterventionsPaper
Current Gene Therapy·May 8Hutchinson-Gilford Progeria Syndrome: Genetic Insights, Clinical Challenges, and Innovative Therapeutic ApproachesReviewProgeriaPaper
Jentashapir Journal of Cellular and Molecular Biology·Mar 31Antisense Oligonucleotides as Precision Therapies for Neurodegenerative Diseases: A Narrative ReviewReviewAntisense oligonucleotidesPaper
Journal of Clinical Medicine·Mar 28Existing and Potential Therapeutic Strategies for Lowering Lipoprotein(a) Levels: An UpdateReviewInterventionsPaper
Cureus·Mar 23RNA-Based Therapies for Hypercholesterolemia and Coronary Artery DiseaseReviewHypercholesterolemiaPaper
Anatolian Journal of Cardiology·Mar 18Managing Progressive Atherosclerotic Cardiovascular Disease in a Patient with Elevated Lipoprotein(a)ReviewAtherosclerotic cardiovascular diseasePaper
Journal of Advanced Research·Mar 4From scaffold to effector: reframing GFAP in neurodegenerationSystematic reviewMechanismsPaper
European Heart Journal·Feb 13Lipoprotein(a)-lowering therapies: a promising futureReviewInterventionsPaper
Chemical Science·Feb 4Navigating the next frontier in biomedicine: breakthroughs and insights in nucleic acid therapeuticsReviewInterventionsPaper
Materials Today Bio·Feb 2Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translationReviewLipid nanoparticlesPaper
Pharmacological Reviews·Jan 30From physiopathology to treatment of familial hypercholesterolemia: Existing and emerging pharmacotherapiesReviewPharmacotherapyPaper